Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 13 (3), 305-15

Delamanid (OPC-67683) for Treatment of Multi-Drug-Resistant Tuberculosis

Affiliations
Review

Delamanid (OPC-67683) for Treatment of Multi-Drug-Resistant Tuberculosis

Giovanni Sotgiu et al. Expert Rev Anti Infect Ther.

Abstract

The research and development of delamanid was carried out by Otsuka Pharmaceutical Development and Commercialization (Osaka, Tokyo, Japan). It belongs to the group of nitroimidazoles. It inhibits the synthesis of mycolic acids, crucial component of the cell wall of the Mycobacterium tuberculosis complex. It is insoluble in water and its activity was proven in several in vitro and in vivo studies. Its market approval was obtained in April 2014 in Europe. Its bactericidal activity was demonstrated in individuals with drug-susceptible and drug-resistant tuberculosis (MDR- and XDR-TB). The safety and tolerability profile was good; the notified increased QT interval was not clinically relevant. It was approved for adults but ongoing clinical trials and clinical experiences have been proving its efficacy in the pediatric population.

Keywords: MDR-TB prevention; delamanid; mycolic acid inhibition; nitro-dihydro-imidazooxazole; tuberculosis.

Similar articles

See all similar articles

Cited by 12 articles

See all "Cited by" articles

MeSH terms

LinkOut - more resources

Feedback